Exubrion Therapeutics, Buford, GA, United States of America.
Gulf Coast Veterinary Specialists, Houston, TX, United States of America.
PLoS One. 2021 Jul 19;16(7):e0254613. doi: 10.1371/journal.pone.0254613. eCollection 2021.
The radionuclide 117mSn (tin-117m) embedded in a homogeneous colloid is a novel radiosynoviorthesis (RSO) device for intra-articular (IA) administration to treat synovial inflammation and mitigate osteoarthritis (OA) in dogs. A study to evaluate tin-117m colloid treatment response in dogs with OA was conducted at two centers, the School of Veterinary Medicine at Louisiana State University, and at a referral practice in Houston, Texas. The tin-117m colloid was administered per-protocol to 14 client-owned dogs with radiographically confirmed, grade 3 OA in one or both elbow joints. Dog owners and attending clinicians assessed the level of pain at baseline (BL) and the post-treatment pain response at 90-day intervals for one year. Owners assessed treatment response according to a pain severity score (PSS) and a pain interference score (PIS) as defined by the Canine Brief Pain Inventory. Clinicians reported a lameness score using a 0-5 scale, from no lameness to continuous non-weight bearing lameness, when observing dogs at a walk and a trot. The rate of treatment success as determined by improved mean PSS and PIS scores reported by dog owners was >70% at all time points. Clinicians reported an improved mean pain score from BL at post-treatment Days 90 (p<0.05), 180, and 270. The dog owner and clinician assessments of treatment success were significantly correlated (p>0.05) at Day 90 and Day 180 time points. Results indicated that a single IA dose of tin-117m colloid provided a significant reduction in pain and lameness and improved functionality for up to a full year, with no adverse treatment related effects, in a high percentage of dogs with advanced, clinical OA of the elbow joint.
放射性核素 117mSn（锡-117m）嵌入均匀胶体中，是一种新型的放射性滑膜切除术（RSO）设备，可用于关节内（IA）给药，以治疗滑膜炎症和减轻犬的骨关节炎（OA）。在路易斯安那州立大学兽医学院和德克萨斯州休斯顿的一家转诊诊所的两个中心进行了一项研究，以评估锡-117m 胶体治疗 OA 犬的反应。根据方案将锡-117m 胶体给予 14 只经放射学证实的、一只或两只肘关节均为 3 级 OA 的患犬。犬主人和主治临床医生在基线（BL）时评估疼痛程度，并在一年中每 90 天评估一次治疗后的疼痛反应。根据犬的简短疼痛量表（CBS）定义的疼痛严重程度评分（PSS）和疼痛干扰评分（PIS），主人评估治疗反应。临床医生在观察狗行走和小跑时，使用 0-5 分制报告跛行评分，从无跛行到持续非负重跛行。根据犬主人报告的 PSS 和 PIS 评分改善情况，确定治疗成功率>70%。临床医生报告治疗后第 90 天（p<0.05）、第 180 天和第 270 天的平均疼痛评分有所改善。犬主人和临床医生对治疗成功的评估在第 90 天和第 180 天时间点具有显著相关性（p>0.05）。结果表明，在患有进展性、临床性肘关节 OA 的犬中，单次 IA 剂量的锡-117m 胶体可显著减轻疼痛和跛行，提高功能，长达一年，且无不良治疗相关影响。
